secwatch.observer — SEC 8-K summary
======================================

Issuer:     BICYCLE THERAPEUTICS PLC (BCYC)
CIK:        0001761612
Form:       8-K
Filed at:   2025-04-29T23:59:59+00:00
Accession:  0001104659-25-040625
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicycle Therapeutics presents positive MT1-MMP imaging data from 12 solid tumor patients at AACR 2025
--------------------------------------------------------------------------------

- Data from 12 patients validate MT1-MMP as cancer target; BRC tracer showed uptake in primary tumors and metastases.
- In lung cancer patient, MT1-MMP-PET showed BRC uptake in primary tumor (SUVmax 6.0) and bone metastases (SUVmax 7.9).
- In breast/bladder cancer patient, MT1-MMP-PET revealed higher uptake than CT; IHC confirmed MT1-MMP expression in tumor.
- Second BRC molecule targeting EphA2: initial human imaging data expected 2H 2025; company-sponsored trials planned for 2026.
- Overall, 12 of 14 patients imaged successfully; results support radiopharmaceutical therapy potential.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761612/000110465925040625/0001104659-25-040625-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761612/000110465925040625/tm2513386d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-040625

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer